AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|
24.8 C
New York
Tuesday, July 21, 2026

Tag: dialysis

newssourceFORcompanyinformationcontent1releasesmarket

Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production

Uni Hospital Successfully Renews Global Healthcare Accreditation, Strengthening Bulgaria’s Position in International Patient Services

WEST PALM BEACH, Fla., June 9, 2026 /PRNewswire/ -- Global Healthcare Accreditation (GHA) is pleased to announce that Uni Hospital, located in Panagyurishte, Bulgaria,...

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...

New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home

New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis

Gujarat becomes the New Hub in Organ Transplantation

Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...

Philippines’ AC Health partners with Singapore’s ABC Impact in vision to transform health for every Filipino

MANILA, Philippines, Aug. 11, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the...

Philippines’ AC Health partners with Singapore’s ABC Impact in vision to transform health for every Filipino

MANILA, Philippines, Aug. 11, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the...

Philippines’ AC Health partners with Singapore’s ABC Impact in vision to transform health for every Filipino

MANILA, Philippines, Aug. 10, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. – UNCY

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb

New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use.

Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics

CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging SystemThe VxWave Ultrasound Imaging System potentially provides important insights...

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

Somatus Surpasses 500,000 Patients Actively Under Management Across All 50 States and DC

Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services MCLEAN, Va., July 22,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDialysis

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers